![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ELI LILLY LICENSES TAISHO DIABETES DRUG
ELI LILLY LICENSES TAISHO DIABETES DRUG
July 7, 2005
Drug maker Eli Lilly said Wednesday that it signed a licensing agreement with Japanese drug maker Taisho Pharmaceutical to eventually market a novel Type 2 diabetes treatment currently in development. Under the agreement, Lilly gets exclusive rights to develop and market Taisho's TS-021, a diabetes treatment that inhibits an enzyme responsible for breaking down a hormone crucial to maintaining blood sugar levels.
Forbes (http://www.forbes.com/business/energy/feeds/ap/2005/07/06/ap2125116.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct